Search

Your search keyword '"Masamitu Karasawa"' showing total 2 results
Start Over Author "Masamitu Karasawa"
2 results on '"Masamitu Karasawa"'

1. Clinical Efficacy of Fosfomycin in Combination with Sulbactam/Cefoperazone in the Treatment of Severe Infections Complicated to Blood Dyscrasia

Author

Kiyoshi KITAMURA, Hisamaru HIRAI, Noriko HOSOYA, Masao SUGAI, Masamitu KARASAWA, Takuji NARUSE, Yasusada MIURA, Ken OHMINE, Syojiro TAKAGI, Kunitake HIRASHIMA, Masami BESSHO, Masataka FUKUDA, Nobutaka KAWAI, Kazuo DAN, Emi AN, Tetsuo HOSHINO, Kazuo OSHIMI, Masaaki NOGUCHI, Motoki EGASHIRA, Yasuo IKEDA, Masahiro KIZAKI, Keisuke TOYAMA, Keisuke MIYAZAWA, Masaya NAGASU, Yuka INATOMI, Yuzuru KURIYAMA, Osamu IWASE, Hideaki MIZOGUCHI, Shoko KOBAYASHI, Nobuyoshi TSURUOKA, Shigeru TOMOYASU, Tsuyoshi NAKAMAKI, Yoshihisa AKIMOTO, Tsunayuki KAKIMOTO, Yoshitomo MUTO, Junichi UEYAMA, Atsushi TOGAWA, Akiyoshi MIWA, Mari NAGAI, Akio URABE, Mitsue ENDO, Mayumi MORI, Ken KURAMOTO, Masayuki KIKUKAWA, Noriko NAKAMURA, Kenshi SUZUKI, Yasuyuki INOUE, Masakazu SAWANOBORI, Yasuaki NAKAGAWA, Kyozo ISHIKAWA, Koichi KAWANO, Masashi HOMORI, Yoshiro MURAI, Ryoko MIZUTANI, Kyoko NAKAMURA, Mitsuhiro OMINE, Hikaru FUJIWARA, Shyozo CHIBA, and Akira HIRASAWA

Subjects
medicine.medical_specialty, Combination therapy, business.industry, medicine.drug_class, Antibiotics, General Medicine, Sulbactam, Fosfomycin, Gastroenterology, Dyscrasia, Group B, Surgery, Cefoperazone, Internal medicine, Absolute neutrophil count, medicine, business, medicine.drug
Abstract

In the treatment of severe infections complicated to blood dyscrasia, the efficacy and usefulness of fosfomycin (FOM) in combination with sulbactam (SBT)/cefoperazone (CPZ) were compared between patients receiving FOM in the first followed by SBT/CPZ (Group A) and those receiving both drugs simultaneously (Group B). The following results were obtained. 1. The efficacy rate was 56.3% for Group A and 47.9% for Group B, with no significant difference. 2. The efficacy for patients suspected of the presence of septicemia, the efficacy rate was 57.9% for Group A and 54.3% for Group B, with no significant difference. 3. As for underlying disease, patients with acute myelogenous leukemia were most prevailing. In these patients, the efficacy rate was 57.1% for Group A and 27.3% for Group B, with no statistically significant difference. However, the efficacy rate tended to be higher in Group A. 4. The administration of antibiotics was effective to restore the neutrophil count to 501/microliters or higher in 77.8% and 45.5% of the cases for Groups A and B, respectively, with significantly higher efficacy for Group A. 5. In the safety evaluation a total of 115 cases were included. Side effects and laboratory abnormalities were seen in 3 cases each, but none of them were serious in degree. From these results, it was confirmed that the combination therapy consisting of administration of FOM followed by SBT/CPZ with some interval is effective for severe infections complicated to blood dyscrasia.

Published
1998

2. Two cases of chronic graft-versus-host disease with elevated levels of soluble Fas ligand in serum

Author

T Matsushima, Shuichi Miyawaki, Masamitu Karasawa, Nahoko Hatsumi, J Tamura, Toru Sakura, Takayuki Saito, and Satoru Takada

Subjects
Male, Fas Ligand Protein, Adolescent, Prednisolone, Graft vs Host Disease, chemical and pharmacologic phenomena, Disease, Fas ligand, Pathogenesis, immune system diseases, medicine, Humans, Membrane Glycoproteins, business.industry, Hematology, Middle Aged, medicine.disease, Ligand (biochemistry), Soluble fas ligand, surgical procedures, operative, Graft-versus-host disease, Liver, Solubility, Immunology, Chronic Disease, Cyclosporine, Chronic gvhd, Female, Liver dysfunction, business, Immunosuppressive Agents
Abstract

It has recently been shown that the Fas-Fas ligand (FasL) system may be one of the pathogeneses for acute graft-versus-host disease (GVHD), and it has been reported that serum soluble Fas ligand (sFasL) increases with the presence of acute GVHD. However, there is no report on a correlation between the Fas-FasL system and chronic GVHD. We present two cases of chronic GVHD with elevated levels of serum sFasL. Its level in each case was high at the onset of chronic GVHD, but it decreased with steroid therapy. Liver dysfunction also improved as the level of serum sFasL decreased. It appears in these cases that the Fas-FasL system was related to the pathogenesis of liver damage.

Published
2000

Catalog

Books, media, physical & digital resources
See catalog results